Skip Navigation

European Journal of Echocardiography 2008 9(1):60-62; doi:10.1016/j.euje.2006.08.015
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Arnold, J. R.
Right arrow Articles by Ormerod, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, J. R.
Right arrow Articles by Ormerod, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2006. For permissions please email: journals.permissions@oxfordjournals.org.

Ventricular septal rupture following abciximab infusion

Jayanth R. Arnold*, Jonathan Timperley, Andrew R.J. Mitchell, Stephen Westaby and Oliver Ormerod

Department of Cardiology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK

Received 27 July 2006; accepted after revision 29 August 2006; online publish-ahead-of-print 11 October 2006.

* Corresponding author. Tel: + 44 01865 228934; fax: +44 01865 220585. E-mail address: ranjitarnold{at}yahoo.co.uk


  Abstract

Ventricular septal rupture is a rare complication of myocardial infarction. Despite a significant reduction in its incidence with reperfusion therapy, thrombolysis has been implicated in the pathogenesis of septal rupture. There is little information regarding the impact of glycoprotein IIb–IIIa receptor blockers on ventricular septal rupture. We report a case of rupture of the ventricular septum occurring after treatment with the glycoprotein IIb–IIIa receptor blocker abciximab, in the absence of thrombolysis.

Keywords: Ventricular septal defect; Abciximab; Myocardial infarction; Surgical repair


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.